Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$0.86
+1.5%		$1.11
$0.62
▼
$5.50
$37.13M1.361.08 million shs417,292 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.34
-7.8%		$0.59
$0.34
▼
$1.30
$45.11M1.261.25 million shs516,038 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-0.94%+28.64%-20.38%-54.47%-65.43%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-9.62%-17.11%-24.08%-55.40%-67.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$0.86
+1.5%		$1.11
$0.62
▼
$5.50
$37.13M1.361.08 million shs417,292 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.34
-7.8%		$0.59
$0.34
▼
$1.30
$45.11M1.261.25 million shs516,038 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-0.94%+28.64%-20.38%-54.47%-65.43%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-9.62%-17.11%-24.08%-55.40%-67.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
2.25
Hold$12.001,328.57% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.00
Hold$5.001,244.09% Upside

Current Analyst Ratings Breakdown

Latest ANVS and ONCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
11/10/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/26/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/9/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/2/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/27/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$8.00 ➝ $7.00
8/19/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$5.00
8/18/2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.64 per shareN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A($0.04) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$28.85M-$1.79N/AN/AN/AN/A-685.98%-258.77%N/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$28.76M-$0.34N/AN/AN/AN/AN/A-442.99%N/A

Latest ANVS and ONCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.4533-$0.40+$0.0533-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
3.47
3.47
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
1.35
1.35

Institutional Ownership

CompanyInstitutional Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%

Insider Ownership

CompanyInsider Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.92%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
4.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
743.02 million36.17 millionOptionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
29131.12 million124.99 millionNot Optionable

Recent News About These Companies

Oncolytics Partners With Coherus For Testing Pelareorep+LOQTORZI Combination In Anal Carcinoma
November 12 at 4:35 AM  |  rttnews.comhttps://www.rttnews.com/3713693/oncolytics-partners-with-coherus-for-testing-pelareorep-loqtorzi-combination-in-anal-carcinoma.aspx
Oncolytics signs LOQTORZI supply deal for planned anal cancer study
November 11 at 5:43 PM  |  msn.comhttps://www.msn.com/en-ca/news/other/oncolytics-signs-loqtorzi-supply-deal-for-planned-anal-cancer-study/ar-AA2hf6TX
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
November 11 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/11/3401132/0/en/oncolytics-biotech-announces-clinical-supply-agreement-to-evaluate-pelareorep-in-combination-with-loqtorzi-toripalimab-tpzi-in-squamous-cell-anal-carcinoma.html
Oncolytics Biotech (ONCY) Projected to Post Earnings on Wednesday
November 10 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189089
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
November 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398560/0/en/pelareorep-induces-coordinated-antiviral-immune-responses-and-enhanced-antitumor-immunity-in-multiple-myeloma-patients.html
Oncolytics Biotech stock: GOBLET findings strengthen pelareorep case
November 4, 2026  |  ad-hoc-news.deA
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
November 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395466/0/en/translational-data-from-anal-cancer-patients-show-pelareorep-drives-hpv-specific-immune-responses-supporting-its-potential-across-hpv-driven-cancers.html
Oncolytics Biotech (ONCY) Set to Post Quarterly Earnings on Wednesday
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-oncolytics-biotech-oncy-set-to-post-quarterly-earnings-on-wednesday-2026-11-04/
Oncolytics Biotech stock: GOBLET data show durable anal-cancer responses
October 30, 2026  |  ad-hoc-news.deA
Oncolytics Biotech Reports Durable Responses in GOBLET Cohort 4 Anal Cancer Study and Advances Pelareorep Toward Registration
October 27, 2026  |  quiverquant.comQ
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389148/0/en/oncolytics-biotech-reports-strong-durability-and-survival-data-in-anal-cancer-positioning-pelareorep-as-potential-backbone-immunotherapy-across-hpv-driven-cancers.html
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384572/0/en/oncolytics-biotech-to-present-reo-033-trial-in-progress-abstract-at-esmo-showcasing-pelareorep-s-potential-in-colorectal-cancer.html
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% - Here's Why
October 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-oncolytics-biotech-nasdaq-oncy-stock-price-up-98-heres-why-2026-10-14/
Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment
October 14, 2026  |  rttnews.comhttps://www.rttnews.com/3699010/oncolytics-updates-goblet-study-data-timelines-expects-final-pancan-grant-payment.aspx
Oncolytics Biotech Announces Completion of GOBLET Enrollment and Updates Timeline for Cohort 4 and 5 Results
October 14, 2026  |  quiverquant.comQ
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380838/0/en/oncolytics-biotech-provides-update-on-goblet-study-clinical-data-and-final-pancan-grant-payment.html
Oncolytics Biotech Details on Intellectual Property Strategy
October 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oncolytics-biotech-details-intellectual-property-214257577.html
Oncolytics Biotech Reports Progress on Pelareorep Patent Portfolio, Including New Method-of-Use Issuance and Planned Next-Generation Protection
October 12, 2026  |  quiverquant.comQ
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
October 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/12/3379237/0/en/oncolytics-biotech-secures-patent-protection-to-late-2040s-and-provides-intellectual-property-portfolio-update.html
Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695277/oncolytics-highlights-pelareorep-preclinical-findings-in-hepatocellular-carcinoma.aspx
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370999/0/en/oncolytics-biotech-announces-publication-demonstrating-pelareorep-creates-immune-responses-in-liver-cancer-that-make-tumors-susceptible-to-immunotherapy.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$0.86 +0.01 (+1.51%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$0.34 -0.03 (-7.80%)
As of 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas